Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Cash & Equivalents for 8 consecutive years, with $71.2 million as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents fell 6.22% to $71.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.2 million through Feb 2026, down 6.22% year-over-year, with the annual reading at $247.0 million for FY2025, 124.52% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $71.2 million at Nurix Therapeutics, down from $247.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $247.0 million in Q4 2025, with the low at $33.6 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $79.7 million, with a median of $71.2 million recorded in 2026.
  • The sharpest move saw Cash & Equivalents tumbled 77.93% in 2022, then skyrocketed 134.12% in 2024.
  • Over 5 years, Cash & Equivalents stood at $64.5 million in 2022, then decreased by 15.27% to $54.6 million in 2023, then surged by 101.36% to $110.0 million in 2024, then soared by 124.52% to $247.0 million in 2025, then plummeted by 71.17% to $71.2 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $71.2 million, $247.0 million, and $78.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.